Evidence map›Paper›PMID 36344918›Full record

ArticleBMC geriatrics2022

Factors associated with polypharmacy and the high risk of medication-related problems among older community-dwelling adults in European countries: a longitudinal study.

Lizhen Ye, Junwen Yang-Huang, Carmen Betsy Franse, Tomislav Rukavina, Vanja Vasiljev, Francesco Mattace-Raso, Arpana Verma, Tamara Alhambra Borrás, Tasos Rentoumis, Hein Raat

Open access · goldAbstract read
In one paragraph

Article in BMC geriatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 7 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 7 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Contribution of Obesity to Polypharmacy in U.S. Older Adults.Journal of general internal medicine · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Lizhen YeDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, P.O, . Box 2040, 3000 CA, Rotterdam, The Netherlands.
Junwen Yang-HuangDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, P.O, . Box 2040, 3000 CA, Rotterdam, The Netherlands.
Carmen Betsy FranseDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, P.O, . Box 2040, 3000 CA, Rotterdam, The Netherlands.
Tomislav RukavinaDepartment of Social Medicine and Epidemiology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
Vanja VasiljevDepartment of Social Medicine and Epidemiology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia.
Francesco Mattace-RasoDepartment of Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Arpana VermaEpidemiology and Public Health Group, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK.
Tamara Alhambra BorrásPolibienestar Research Institute - Universitat de València ES, Valencia, Spain.
Tasos RentoumisAlliance for Integrated Care, Athens, Greece.
Hein RaatDepartment of Public Health, Erasmus MC, University Medical Center Rotterdam, P.O, . Box 2040, 3000 CA, Rotterdam, The Netherlands. h.raat@erasmusmc.nl.
Erasmus MC · NLUniversity of Rijeka · HRManchester Academic Health Science Centre · GBUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolypharmacy can be defined as using five or more medications simultaneously. "Medication-related problems", an extension of polypharmacy, includes inappropriate prescribing, poor adherence, overdosage, underdosage, inappropriate drug selection, inadequate monitoring, adverse drug effects, and drug interactions. Polypharmacy and the high risk of medication-related problems among older people are associated with adverse health consequences due to drug-drug interactions, drug-disease interactions, and adverse drug effects. This study aims to assess the factors associated with polypharmacy and the high risk of medication-related problems among community-dwelling older people in the Netherlands, Greece, Croatia, Spain, United Kingdom.

methodThis longitudinal study used baseline and follow-up data from 1791 participants of the Urban Health Center European project. Polypharmacy and the risk of medication-related problems were evaluated at baseline and follow-up using the Medication Risk Questionnaire. We studied factors in the domains (a) sociodemographic characteristics, (b) lifestyle and nutrition, and (c) health and health care use. Hierarchical logistic regression analyses were used to examine the factors associated with polypharmacy and the high risk of medication-related problems.

resultsMean age was 79.6 years (SD ± 5.6 years); 60.8% were women; 45.2% had polypharmacy, and 41.8% had a high risk of medication-related problems. Women participants had lower odds of polypharmacy (OR = 0.55;95%CI:0.42-0.72) and a high risk of medication-related problems (OR = 0.50; 95%CI:0.39-0.65). Participants with a migration background (OR = 1.67;95%CI:1.08-2.59), overweight (OR = 1.37; 95%CI:1.04-1.79) and obesity (OR = 1.78;95%CI:1.26-2.51) compared to 'normal weight', with lower physical HRQoL (OR = 0.96, 95%CI:0.95-0.98), multi-morbidity (OR = 3.73, 95%CI:2.18-6.37), frailty (OR = 1.69, 95%CI:1.24-2.30), visited outpatient services (OR = 1.77, 95%CI: 1.09-2.88) had higher odds of polypharmacy. The associations with the high risk of medication-related problems were similar.

conclusionsMultiple factors in demography, lifestyle, nutrition, and health care use are associated with polypharmacy and the high risk of medication-related problems. Polypharmacy is a single element that may reflect the number of medications taken. The broader content of medication-related problems should be considered to assess the context of medication use among older people comprehensively. These provide starting points to improve interventions to reduce polypharmacy and high risk of medication-related problems. In the meantime, health professionals can apply these insights to identify subgroups of patients at a high risk of polypharmacy and medication-related problems.

trial registrationThe intervention of the UHCE project was registered in the ISRCTN registry as ISRCTN52788952. The date of registration is 13/03/2017.

Indexed as

Drug-Related Side Effects and Adverse ReactionsPolypharmacyAgedEuropeFemaleHumansInappropriate PrescribingIndependent LivingLongitudinal StudiesMalePolypharmacy; Medication-related problems; Older people; Sex; Migration background, BMI, frailty, outpatient services, Health related quality of life

Identifiers

PMID36344918
PMCPMC9641844
OpenAlexW4308638649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.